Form 4: Galectin Therapeutics CFO Sells Shares Under 10b5-1 Plan

Galectin Therapeutics CFO Jack W. Callicutt sold common stock on November 5, 2025, through pre-planned option exercises and sales.

Summary

• Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics Inc. (GALT), reported transactions involving the company's common stock and derivative securities on November 5, 2025.
• The transactions were executed under a Rule 10b5-1 plan adopted on April 17, 2025, and previously disclosed in the Issuer's Quarterly Report on Form 10-Q filed on August 14, 2025.
• Callicutt exercised stock options to acquire a total of 600 shares of common stock. These options had exercise prices of $1.98 (200 shares), $1.11 (200 shares), and $1.72 (200 shares).
• Concurrently, Callicutt sold a total of 600 shares of common stock at a price of $6.00 per share.
• Following these transactions, Callicutt's direct beneficial ownership of common stock is 7,614 shares.
• Remaining derivative securities (stock options) include 39,586 options with a $1.98 exercise price, 39,566 options with a $1.11 exercise price, and 52,809 options with a $1.72 exercise price.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (option exercises and sales) executed under a pre-established 10b5-1 plan, which is a neutral event and does not indicate new material information.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 plan, indicating a pre-scheduled event rather than a reaction to new, undisclosed information.
• The sale price of $6.00 per share is significantly higher than the option exercise prices of $1.98, $1.11, and $1.72, indicating a realized gain for the insider.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, though it is a routine event for executive compensation and liquidity management.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a routine aspect of executive compensation and personal financial management across all industries. They typically do not reflect new company-specific or industry-wide developments.

Stakeholder Impact

• Shareholders may note the insider sale, but given it's under a 10b5-1 plan, it is generally considered a routine event with minimal impact on investor sentiment or company valuation.

Key Dates

Recommendation

The filing details a routine insider transaction by the CFO, involving the exercise of stock options and subsequent sale of shares, all executed under a pre-established Rule 10b5-1 plan. Such pre-planned transactions are generally not indicative of new material information or a change in the company's fundamental outlook, thus not warranting a change from a 'hold' recommendation based solely on this filing.

Keywords

Galectin Therapeutics, GALT, Form 4, Insider Transaction, Stock Options, CFO, 10b5-1 Plan, Equity Sales